Rentokil(US:RTO) GlobeNewswire News Room·2024-12-03 17:11Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Rentokil Initial plc due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by January 27, 2025 [2][4]. Company Overview - Rentokil Initial plc is a publicly traded company on the NYSE under the ticker RTO [2]. - The company has faced significant challenges in integrating Terminix, which has negatively impacted its business operations and organic revenue growth in North America [4][7]. Allegations and Financial Impact - The complaint alleges that Rentokil made false or misleading statements regarding its integration of Terminix, failing to disclose execution challenges and disruptions [4]. - Following the release of disappointing financial results for Q1 2024, Rentokil's stock price fell over 9%, from $28.25 to $25.61 per ADS [5][6]. - On September 11, 2024, Rentokil announced a revised expectation of only 1% organic revenue growth for the second half of 2024, leading to a further decline in stock price of over 21%, from $31.60 to $24.95 per ADS [7]. Legal Proceedings - Investors who suffered losses exceeding $75,000 between December 1, 2023, and September 10, 2024, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1]. - The role of lead plaintiff in the class action lawsuit is open to any member of the putative class, with the ability to direct and oversee the litigation [8]. Call for Information - Faruqi & Faruqi is seeking information from whistleblowers, former employees, and shareholders regarding Rentokil's conduct [9].